Zusammenfassung
Die menschliche Lebenserwartung hat sich innerhalb eines relativ kurzen Zeitraums von etwa 100 Jahren nahezu verdoppelt. Ein wesentlicher Faktor war die Verhütung und Behandlung von Infektionskrankheiten durch Impfungen und hochwirksame Medikamente (Antibiotika, Antimykotika, Viruzide). Durch den erfolgreichen Einsatz der Antiinfektiva werden jedoch resistente Erregerformen selektioniert. Deshalb können wir uns bei der Behandlung und Verhütung von Infektionskrankheiten nicht mit dem Erreichten zufrieden geben. Erforderlich wäre vielmehr die fortlaufende Entwicklung neuer Medikamente als Ersatz für Substanzen, die auf Grund der Erregerresistenz nicht mehr für den Einsatz geeignet sind.
Abstract
The human lifespan has been almost doubled over the last century. One of the reasons was the prevention and cure of infectious diseases by vaccination and therapy with highly efficient antibiotics. Unfortunately, the medical application of antibiotics is conducive to the selection of drug‐resistant pathogens. Hence, the therapeutic agents need to be progressively replaced by novel drugs in order to cope with the problem of pathogen resistance.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Arias, C.A. and B.E. Murray, Antibiotic–resistant bugs in the 21st century––a clinical super–challenge. N Engl J Med, 2009. 360(5): p. 439–43.
Woodford, N. and D.W. Wareham, Tackling antibiotic resistance: a dose of common antisense? J Antimicrob Chemother, 2009. 63(2): p. 225–9.
Walsh, C. and G. Wright, Introduction: antibiotic resistance. Chem Rev, 2005. 105(2): p. 391–4.
Neu, H.C., The crisis in antibiotic resistance. Science, 1992. 257(5073): p. 1064–73.
Neu, H.C., et al., Antibiotic resistance. Epidemiology and therapeutics. Diagn Microbiol Infect Dis, 1992. 15(2 Suppl): p. 53S–60S.
Boucher, H.W., et al., Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis, 2009. 48(1): p. 1–12.
Pendleton, J.N., S.P. Gorman, and B.F. Gilmore, Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther, 2013. 11(3): p. 297–308.
Schlitzer, M., Malaria: Lebensrettende Prophylaxe und Therapie. Pharmazeutische Zeitung, 2010(12).
Hobhouse, H., Sechs Pflanzen verändern die Welt. Chinarinde, Zuckerrohr, Tee, Baumwolle, Kartoffel, Kokastrauch. 2001: Klett– Cotta.
Fleming, A., On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ. Br J Exp Pathol, 1929. 10(3): p. 226–36.
Abraham, E.P., et al., Further observations on penicillin. 1941. Eur J Clin Pharmacol, 1992. 42(1): p. 3–9.
Chain, E., et al., Penicillin as a chemotherapeutic agent. 1940. Clin Orthop Relat Res, 1993(295): p. 3–7.
Douglas, N.M., et al., Artemisinin combination therapy for vivax malaria. Lancet Infect Dis, 2010. 10(6): p. 405–16.
Helmstädter, A., 100 Jahre Salvarsan: Chemisch auf Erreger zielen Pharmazeutische Zeitung, 2010. 52.
Domagk, G.J.P., Beitrag zur Chemotherapie der bakteriellen Infektionen. Deutsch. Med. Wochenschrift, 1935. 61: p. 250–253.
Grundmann, E., Gerhard Domagk. Ein Pathologe besiegt die bakteriellen Infektionskrankheiten. Der Pathologe, 2001. 22.
Fischer, M., B. Thöny, and S. Leimkühler, The Biosynthesis of Folate and Pterins and Their Enzymology. Comprehensive Natural Products II: Chemistry and Biology ed. L.M.a.H.–W.B. Liu. Vol. 7. 2010, Oxford: Elsevier.
Reynolds, C.H., B.A. Tounge, and S.D. Bembenek, Ligand binding efficiency: trends, physical basis, and implications. J Med Chem, 2008. 51(8): p. 2432–8.
Fleischmann, R.D., et al., Whole–genome random sequencing and assembly of Haemophilus influenzae Rd. Science, 1995. 269(5223): p. 496–512.
Blundell, T.L., H. Jhoti, and C. Abell, High–throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov, 2002. 1(1): p. 45–54.
Engelman, A. and P. Cherepanov, The structural biology of HIV–1: mechanistic and therapeutic insights. Nat Rev Microbiol, 2012. 10(4): p. 279–90.
Jaskolski, M., et al., Structure at 2.5–A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene–based inhibitor. Biochemistry, 1991. 30(6): p. 1600–9.
Seelmeier, S., et al., Human immunodeficiency virus has an aspartic– type protease that can be inhibited by pepstatin A. Proc Natl Acad Sci U S A, 1988. 85(18): p. 6612–6.
Kohl, N.E., et al., Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A, 1988. 85(13): p. 4686–90.
Tie, Y., et al., Atomic resolution crystal structures of HIV–1 protease and mutants V82A and I84V with saquinavir. Proteins, 2007. 67(1): p. 232–42.
Houston, J.G., The impact of automation on high–throughput screening. Methods Find Exp Clin Pharmacol, 1997. 19 Suppl A: p. 43–5.
Macarron, R., et al., Impact of high–throughput screening in biomedical research. Nat Rev Drug Discov, 2011. 10(3): p. 188–95.
Snowden, M. and D.V. Green, The impact of diversity–based, highthroughput screening on drug discovery: "chance favours the prepared mind". Curr Opin Drug Discov Devel, 2008. 11(4): p. 553–8.
McInnes, C., Virtual screening strategies in drug discovery. Curr Opin Chem Biol, 2007. 11(5): p. 494–502.
Rester, U., From virtuality to reality – Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr Opin Drug Discov Devel, 2008. 11(4): p. 559–68.
Rollinger, J.M., H. Stuppner, and T. Langer, Virtual screening for the discovery of bioactive natural products. Prog Drug Res, 2008. 65: p. 211, 213–49.
Metzker, M.L., Sequencing in real time. Nat Biotechnol, 2009. 27(2): p. 150–1.
Metzker, M.L., Sequencing technologies – the next generation. Nat Rev Genet, 2010. 11(1): p. 31–46.
Diacon, A.H., et al., The diarylquinoline TMC207 for multidrugresistant tuberculosis. N Engl J Med, 2009. 360(23): p. 2397–405.
Haagsma, A.C., et al., Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother, 2009. 53(3): p. 1290–2.
Matteelli, A., et al., TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol, 2010. 5(6): p. 849–58.
Shang, S., et al., Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother, 2011. 55(1): p. 124–31.
Baker, M., Fragment-based lead discovery grows up. Nat Rev Drug Discov, 2013. 12(1): p. 5–7.
Erlanson, D.A., Introduction to fragment-based drug discovery. Top Curr Chem, 2012. 317: p. 1–32.
Rees, D.C., et al., Fragment-based lead discovery. Nat Rev Drug Discov, 2004. 3(8): p. 660–72.
Clarke, T., Drug companies snub antibiotics as pipeline threatens to run dry. Nature, 2003. 425(6955): p. 225.
Madigan, M.T., J.M. Matinko, and J. Parker, Brock Miikrobiologie. Vol. 1. Auflage. 2001, Heidelberg, Berlin: Spektrum Akademischer Verlag.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Fachmedien Wiesbaden
About this chapter
Cite this chapter
Fischer, M., Bacher, A. (2014). Wege zu neuen Medikamenten gegen Infektionskrankheiten. In: Fischer, M. (eds) Neue und alte Infektionskrankheiten. Springer Spektrum, Wiesbaden. https://doi.org/10.1007/978-3-658-04124-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-658-04124-3_1
Published:
Publisher Name: Springer Spektrum, Wiesbaden
Print ISBN: 978-3-658-04123-6
Online ISBN: 978-3-658-04124-3
eBook Packages: Life Science and Basic Disciplines (German Language)